Whitehawk Therapeutics (NASDAQ:WHWK) CEO Sells $322,718.41 in Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CEO David James Lennon sold 94,087 shares of the business’s stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $3.43, for a total transaction of $322,718.41. Following the sale, the chief executive officer directly owned 597,067 shares in the company, valued at $2,047,939.81. This trade represents a 13.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David James Lennon also recently made the following trade(s):

• On Thursday, April 9th, David James Lennon sold 14,500 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.38, for a total transaction of $49,010.00.
• On Wednesday, April 8th, David James Lennon sold 63,945 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.40, for a total transaction of $217,413.00.
• On Monday, April 6th, David James Lennon sold 102,395 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.51, for a total transaction of $359,406.45.
• On Thursday, April 2nd, David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.48, for a total transaction of $93,465.84.
• On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total transaction of $16,881.00.

Whitehawk Therapeutics Stock Performance

Shares of WHWK stock opened at $3.39 on Friday. The firm’s 50-day moving average is $3.35 and its 200-day moving average is $2.71. The stock has a market cap of $160.01 million, a price-to-earnings ratio of 7.21 and a beta of 0.57. Whitehawk Therapeutics, Inc. has a 52-week low of $1.39 and a 52-week high of $4.48.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.21.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Quadrature Capital Ltd bought a new position in shares of Whitehawk Therapeutics during the fourth quarter worth approximately $28,000. ABG Innovation Capital Partners III GP Ltd bought a new position in shares of Whitehawk Therapeutics during the third quarter worth approximately $51,000. Dimensional Fund Advisors LP bought a new position in shares of Whitehawk Therapeutics during the third quarter worth approximately $84,000. Squarepoint Ops LLC bought a new position in shares of Whitehawk Therapeutics during the third quarter worth approximately $159,000. Finally, Marshall Wace LLP bought a new position in shares of Whitehawk Therapeutics during the fourth quarter worth approximately $164,000. 52.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on WHWK shares. Oppenheimer started coverage on shares of Whitehawk Therapeutics in a report on Thursday, February 5th. They issued an “outperform” rating and a $6.00 target price on the stock. JonesTrading started coverage on shares of Whitehawk Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $7.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Friday, March 27th. Finally, Wall Street Zen cut shares of Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $6.50.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.